MAI Therapeutics
MAI Therapeutics uses AI to generate novel small-molecule candidates, accelerating early-stage drug discovery for pharmaceutical teams. The company applies a generative network platform and mathematical artificial intelligence software to design new molecular entities and explore chemical space. Its approach combines generative deep learning models and computational chemistry techniques, and the technology is patent-pending and has been used by major pharma partners. MAI competes in the computational drug design category and has been recognized in D3R drug design challenges. The platform targets biopharma and drug discovery groups seeking algorithm-driven candidate generation.
MAI Therapeutics
MAI Therapeutics uses AI to generate novel small-molecule candidates, accelerating early-stage drug discovery for pharmaceutical teams. The company applies a generative network platform and mathematical artificial intelligence software to design new molecular entities and explore chemical space. Its approach combines generative deep learning models and computational chemistry techniques, and the technology is patent-pending and has been used by major pharma partners. MAI competes in the computational drug design category and has been recognized in D3R drug design challenges. The platform targets biopharma and drug discovery groups seeking algorithm-driven candidate generation.